ATYR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ATYR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-12-13), aTyr Pharma's 6-1 Month Momentum % is 83.68%.
The industry rank for aTyr Pharma's 6-1 Month Momentum % or its related term are showing as below:
For the Biotechnology subindustry, aTyr Pharma's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, aTyr Pharma's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where aTyr Pharma's 6-1 Month Momentum % falls into.
6-1 Month Momentum % is calculated as following:
6-1 Month Momentum % | = | ( Price 1-month ago | / | Price 6-month ago | - 1 ) | * | 100 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
aTyr Pharma (NAS:ATYR) 6-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Thank you for viewing the detailed overview of aTyr Pharma's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Paul Schimmel | director | 88 SIDNEY ST, CAMBRIDGE MA 02139 |
Jill Marie Broadfoot | officer: Chief Financial Officer | 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
Sanjay Shukla | officer: Chief Medical Officer | C/O ATYR PHARMA, INC., 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO CA 92121 |
Timothy P Coughlin | director | 339 NORTH GRANADOS AVE, SOLANA BEACH CA 92075 |
Sara Zaknoen | director | C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121 |
John K Clarke | director | C/O CARDINAL HEALTH PARTNERS, 221 NASSAU STREET, PRINCETON NJ 08542 |
Nancy Krueger | officer: See Remarks | C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
Svetlana Lucas | director | 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
Jane A Gross | director | 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121 |
John Mendlein | director, officer: CEO and Executive Chairman | |
Ecor1 Capital Fund Qualified, L.p. | 10 percent owner | 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
Ashraf Amanullah | officer: Vice President, Manufacturing | C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
John T Blake | officer: Vice President, Finance | C/O SECOND SIGHT MEDICAL PRODUCTS, INC., 12744 SAN FERNANDO ROAD, SUITE 400, SYLMAR CA 91342 |
Jeffrey S. Hatfield | director | 11080 ROSELLE STREET, SAN DIEGO CA 92121 |
David John King | officer: See Remarks | 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
From GuruFocus
By sperokesalga sperokesalga • 05-25-2023
By Marketwired • 08-06-2024
By Marketwired • 07-30-2024
By GuruFocus News • 11-07-2024
By Marketwired • 08-21-2024
By Marketwired • 08-09-2023
By sperokesalga sperokesalga • 05-22-2023
By Marketwired • 08-24-2023
By sperokesalga sperokesalga • 06-20-2023
By Marketwired • 05-24-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.